Rapid Immunoassay Distinguishes Between COVID-19 and Seasonal Flu Infections In 10 Minutes

Timely diagnosis is essential, as treatment options and infection control measures differ significantly depending on the virus involved. Now, a new diagnostic test can detect and differentiate between these infections from a single sample in just minutes, helping guide faster clinical decisions.

QuidelOrtho (San Diego, CA, USA) has launched the QUICKVUE Influenza + SARS Test, a CLIA-waived and 510(k)–cleared rapid immunoassay. The device allows for simultaneous detection and differentiation of influenza A, influenza B, and SARS-CoV-2 antigens from a single nasal swab sample. Results are available in as fast as 10 minutes, enabling clinicians to distinguish COVID-19 from seasonal flu infections at the point of care.

Designed for use in physician office labs, urgent care centers, emergency departments, pharmacies, and decentralized hospital labs, the QUICKVUE Influenza + SARS Test supports healthcare providers during seasonal surges of respiratory illness. With streamlined processing, a clear result window, and a cost-effective design, the test ensures efficient workflows and affordable access.

The test adds to QuidelOrtho's portfolio of respiratory solutions, including the SOFIA 2 Flu + SARS Antigen FIA, by offering a visually read alternative to its instrumented solutions, strengthening its position in point-of-care respiratory testing. The test is available across the United States through the company’s established distribution network, though it is intended strictly for professional use rather than at-home testing.

“Physician office labs and urgent care centers are on the front lines of respiratory illness diagnosis. With the QUICKVUE Influenza + SARS Test, we're equipping healthcare providers with a reliable, affordable, and efficient tool to differentiate between COVID-19 and influenza in minutes. This innovation reflects QuidelOrtho's commitment to supporting healthcare professionals with cost-effective solutions that streamline clinical decisions and help manage seasonal surges in respiratory infections,” said Tammi Ranalli, PhD, Senior Vice President, Molecular Diagnostics and Point of Care Business Units, QuidelOrtho.